Salmonson, “Pharmacokinetic and Pharmacodynamic Studies on Recombinant Human Erythropoietin”, Scandinavian Journal of Urology and Nephrology, (1990), suppl. 129, pp. 1-66.* |
Salmonson, T., “Pharmacokinetic and Pharmacodynamic Studies on Recombinant Human Erythropoietin,” J. Uro. Nephrol. Suppl. 1990 0(129), pp 1-66. BIOSIS No. 1990:49718, Abstract only. |
Matsushia, et al., “A computer program (PPMODELS) with NeXTSTEP for clculating distribution of drugs based on physiological pharmacokinetic model,” Sch. Med., Kanazawa Univ1996 22(2) pp 123-132 Abstract only. |
Physicians Desk Reference, 51rst ed. (1997) pp 489-495 Medical Economics Company. Inc., Montvale NJ. |
Wichmann, et al., “A mathematical model of erythropoiesis in mice and rats,” Cell Tiissue Kinet. (1989) 22(1) pp 31-49. |
Colburn, et al., “Pharmacokinetic Analysis of Drug Concentration Data Obtained during Repetitive Drug Administration,” J. Pharmaceutical Sci. (1977) 66(4) pp 530-533. |
Walton, et al., “Computer support for determining drug dose systematic review and meta-analysis.” Brit. Medical Journal (1999) 318 pp 984-990. |
McMahon, et al. “Pharmackinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers,” Blood (1990) 76(9) pp1718-1722. |
Hu, Chuanpu, et al. “Comparison of Some Control Strategies for Three-Compartment PK/PD Models,” J. of Pharacokinetics and Biopharmaceutics, Biopharmaceutics 1994 22(6) 525-550. |
Gobburu “Role of dosage regimen in controlling indirect pharmacodynamic responses,” Adv. Drug Delivery Reviews, (1998) 33 pp 221-233. |
Port, R. E. et al., “Predicting the time course of hemoglobin in children treated with erythropoietin for renal anaemia,” Br. J. Clin. Pharmacol (1998) 46(5) pp 461-466. |